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Nontuberculous mycobacterial (NTM) infections are an increasingly recognized
cause of chronic lung disease in immunocompetent adults, and the M. avium
complex, M. kansasii, and a rapidly growing mycobacteria such as M. abscessus,
M. fortuitum, and M. chelonae account for most of the pathogens involved.
Because the clinical features of NTM disease are not distinguishable from those
of tuberculosis, and NTM are ubiquitous in the environment, diagnosis requires
that the bacilli are isolated and identified. NTM diseases have been difficult to
treat, though since the introduction of new macrolides, the outcome for patients
with some NTM diseases has improved significantly. For correct diagnosis and
the successful treatment of NTM pulmonary disease, a knowledge of the full
spectrum of clinical and radiological findings is important.
he clinical importance of tuberculosis distinguishes the Mycobacterium
tuberculosis (M. tuberculosis) complex from all other mycobacteria.
Except for the M. tuberculosis complex and M. leprae, mycobacteria are
referred to collectively as nontuberculous mycobacteria (NTM); previous names for
this group of organisms include ‘environmental mycobacteria,’ ‘atypical mycobacteria,’
or ‘mycobacteria other than tuberculosis,’ though the term NTM is preferred (1, 2).
Unlike M. tuberculosis, which is an obligate human pathogen with no environmental
reservoir, NTM are commonly isolated from environmental sources such as water and
soil, and until the second half of the previous century, occasional isolates of NTM were
thus largely considered contaminants or colonizers (1, 3). Some NTM, however, are
pathogens that may cause severe disease or even death (1 3).
Human disease due to NTM is classified into four distinct clinical syndromes: pul-
monary disease, lymphadenitis, cutaneous disease, and disseminated disease; among
these, chronic pulmonary disease is the most common localized clinical condition (1,
2). The radiologic manifestations of NTM pulmonary disease vary and are often subtle,
and may be indistinguishable from those of tuberculosis. For correct diagnosis and the
successful treatment of the various conditions which may present, a knowledge of the
full spectrum of clinical and radiologic findings is important.
In this article, the authors review the microbiology and epidemiology of NTM
species, and the clinical and radiological manifestations, diagnosis and treatment of the
pulmonary diseases they give rise to, especially in human immunodeficiency virus
(HIV)-negative patients.
MICROBIOLOGY
Within the genus Mycobacterium, four groups of human pathogens can be delineat-
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Ted on the basis of their microbiologic, clinical, and epi-
demiologic characteristics (Table 1). The traditional
Runyon classification of NTM recongnizes these four
groups on the basis of growth rates, colony morphology,
and pigmentation (the Runyon Classification System).
Groups I, II and III are considered slow growers, requiring
a time similar to that required by M. tuberculosis to grow
in culture, while Group IV organisms are rapid growers
which grow well in routine bacteriologic media in less than
seven days. The slow growers are further differentiated ac-
cording to their ability to produce yellow pigment (1). 
This classification system has been primarily a tool for
microbiologists, and has allowed easier identification of in-
dividual NTM species by mycobacterial laboratories.
However, the Runyon classification has become less rele-
vant in recent years due to advances in mycobacteriology,
including more rapid culturing techniques, DNA probes,
and high-pressure liquid chromatography. In addition, this
system is of little value to the clinician, because the organ-
isms in a particular Runyon class may cause quite different
patterns of clinical disease. A more appropriate grouping
for these organisms is currently based on the type of clini-
cal disease they produce: pulmonary disease, lymphadeni-
tis, cutaneous disease, and disseminated disease (1, 2).
EPIDEMIOLOGY
Most NTM are generally environmentally ubiquitous and
have been recovered from water and soil; in humans they
are low-grade pathogens. Person-to-person transmission of
infection is rare, and isolation of infected individuals is thus
not required. It is generally accepted that most human in-
fection is due to environmental NTM, and that airborne
NTM infection may play an important role in respiratory
disease (1, 2).
There is marked geographic variability both in the preva-
lence of disease and in the mycobacterial species responsi-
ble for it. Pulmonary NTM disease in the United States is
most commonly due to the M. avium complex (MAC),
with M. kansasii in second place (1). In the United
Kingdom, M. kansasii is the most common pathogen in
NTM lung disease in England and Wales, while M. mal-
moense is the most common in Scotland. In south-east
England, M. xenopi predominates (2). In Japan, the most
common cause of NTM pulmonary disease is MAC, fol-
lowed by M. kansasii (4).
It is very interesting that the epidemiologic data reported
from Japan are very similar to those from the United
States. Between 1983 and 1984 in Japan, MAC was identi-
fied in approximately 70% of patients with NTM, while M.
kansasii was identified in roughly 25% of such cases (4).
Between 1981 and 1983 in the United States, 62% of
NTM cases were associated with MAC and 24% with M.
kansasii (5). The incidence rates are also very similar be-
tween the two countries: the reported incidence of MAC
lung disease per 100,000 population per year is 1.29 in
Japan and 1.28 in U.S.A., while for M. kansasii, the corre-
sponding figures are 0.34 and 0.33 (4).
In Korea, the reported number of NTM cases has been
rising since the 1980s, though precise epidemiologic data is
not yet available. Earlier investigations of the distribution
of environmental mycobacteria demonstrated that a vari-
ety of NTM species including MAC, M. fortuitum, and M.
chelonae were isolated from Korean soil and water sam-
ples (6). In another report investigating NTM infection in
schoolchildren, involving skin testing of an NTM antigen
comprising M. intracellulare, M. fortuitum, and M. scrofu-
laceum, significant skin reaction was observed in approxi-
mately 10 to 15% of subjects (7).
The first case report of MAC pulmonary disease in Korea
was published in 1981 (8), and a number of cases of pul-
monary disease caused by MAC (9), M. abscessus (10, 11),
M. chelonae (12), M. fortuitum (9) and M. celatum (13) in
HIV-seronegative adults have since been reported. Using
microbiological and clinical data, several papers have de-
tailed the relative frequency of isolated NTM (Tables 2, 3)
(14 17). Synthesis of these various reports shows that the
pathogen most frequently responsible for NTM pulmonary
disease in Korea is MAC, followed by members of the M.
Koh et al.
146 Korean J Radiol 3(3), September 2002









M. kansasii (Photochromogens, Runyon group I)
M. marinum
M. gordonae (Scotochromogens, Runyon group II)
M. scrofulaceum






Rapidly growing mycobacteria (Runyon group IV)
M. fortuitum
M. chelonae
M. abscessusfortuitum and M. chelonae group (including M. abscessus,
formerly known as M. chelonae, subspecies abscessus) (14,
15, 17).
Interestingly, the only case report of M. kansasii pul-
monary disease in Korea involved disseminated M.
kansasii infection in a patient with idiopathic CD4+ T-lym-
phocytopenia (18). In Japan, as previously mentioned, pul-
monary disease caused by M. kansasii has been increasing
since the last 1970s, becoming the second most common
type of NTM pulmonary disease after MAC (4, 19).
CLINICAL PRESENTATION AND DIAGNOSTIC
CRITERIA
Unlike M. tuberculosis, NTM are not obligate pathogens.
Accordingly, the isolation of an NTM species from a respi-
ratory sample is not sufficient evidence of the presence of
NTM lung disease, the diagnosis of which is based on clini-
cal, radiographic, and bacteriologic criteria (1).
The necessary clinical criterion is the presence of com-
patible symptoms and signs, with the reasonable exclusion
of other etiologies of pulmonary disease. However, the
signs and symptoms of NTM lung disease are often vari-
able and nonspecific. Patients fraquently present with
chronic cough, productive sputum, and fatigue. NTM infec-
tion of the lungs often occurs in the context of preexisting
lung disease, especially chronic obstructive pulmonary dis-
ease, bronchiectasis, pneumoconiosis, and previous tuber-
culosis. As a result, the clinical manifestations of NTM lung
disease are often similar to those of the underlying disease
(1).
The radiographic criteria required are the presence of in-
filtrates, cavitation, or multiple nodules at plain chest radi-
ography, and/or multiple small nodules less than 10 mm in
diameter or multifocal bronchiectasis at high-resolution
computed tomography (HRCT) of the lungs (Figs. 1 6),
findings which depend in part on the species involved in
pulmonary infection (Table 4). The well-known radi-
ographic features of NTM lung disease caused by MAC
and M. kansasii are similar to those of postprimary tuber-
culosis (20 23). In these classic upper lung zone diseases,
the most common findings are linear and nodular areas of
increased opacity in the apical and posterior segments of
the upper lobes. In upper lung zone disease, cavitation oc-
curs in about 95% of patients with M. kansasii infection
and approximately 75% of those with MAC infection, fre-
quencies similar to those found in pulmonary tuberculosis
(21, 22). NTM tend to give rise to thinner-walled cavities
and less surrounding parenchymal infiltration than are
found in tuberculosis cases (20, 24), though these classic
forms of MAC or M. kansasii lung disease may be indistin-
guishable from pulmonary tuberculosis (20, 22, 23).
Recent studies involving HRCT of the chest have shown
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Table 2. Frequency of Occurrence of Nontuberculous
Mycobacteria Isolated from Clinical Specimens
Submitted to the Mycobacterial Laboratory of the
Korean Institute of Tuberculosis
Bai et al.(14)Lew et al.(15) KATRD(16)
Study period 1980-1990 1982-1991 1981-1994
No. of isolated specimens 639 83 158
M. avium complex 170 (26.6%) 30 (36.1%) 104 (65.8%)
M. fortuitum 125 (19.6%) 27 (32.5%) 020 (12.7%)
M. chelonae group 0490 (7.7%) 080 (9.6%) 0150 (9.5%)
M. scrofulaceum 0380 (5.9%) 040 (4.8%) 0030 (1.9%)
M. terrae complex 174 (27.2%) 080 (9.6%) 0050 (3.2%)
M. szulgai 0090 (1.4%) 030 (3.6%) 0020 (1.3%)
M. gordonae 0300 (4.7%) 010 (1.2%) 0070 (4.4%)
M. kansasii 0030 (0.5%) 0020 (1.3%)
M. smegmatis 0010 (0.2%)
Others 0400 (6.3%) 020 (2.4%) 0010 (0.6%)
Note. KATRD= Korean Academy of Tuberculosis and Respiratory
Diseases, *M. chelonae group: M. abscessus (formerly M. chelonae,
subspecies abscessus), and M. chelonae (formerly M. chelonae,
subspecies chelonae)
Table 3. Frequency of Occurrence of Isolates of Nontuberculous Mycobacteria in Patients with Proven
Pulmonary Disease According to Published Case Series Studies in Korea
Bai et al. (14) Lew et al. (15) Yoon et al. (17) Total
Study period 1980 1990 1982 1991 1996 1998
No. of patients 59 29 16 104
M. avium complex 29 (49.2%) 19 (65.5%) 11 (68.7%) 59 (56.7%)
M. fortuitum 12 (20.3%) 05 (17.2%) 02 (12.5%) 19 (18.3%)
M. chelonae group    10 (16.9%) 04 (13.8%) 03 (18.8%) 17 (16.3%)
M. scrofulaceum 030 (5.1%) 030 (2.9%)
M. terrae complex 030 (5.1%) 030 (2.9%)
M. szulgai 020 (3.4%) 010 (3.4%) 030 (2.9%)
Note. Nontuberculous mycobacteria were identified in 16 of 30 patients with pulmonary disease,    M. chelonae group: M.
abscessus (formerly M. chelonae, subspecies abscessus) and M. chelonae (formerly M. chelonae, subspecies chelonae)that in many patients with non-cavitary disease of the mid-
dle and lower lung zone caused by MAC pulmonary infec-
tion, both multifocal bronchiectasis and clusters of small
nodules and branching linear structures are present (25
28) (Figs. 2, 4, 6).
In the absence of diagnostic specificity of the clinical
manifestations or chest radiographic findings, the diagnosis
of NTM pulmonary disease requires microbiologic confir-
mation. Positive sputum cultures for NTM must, however,
be interpreted cautiously. The discovery of NTM in a sin-
gle sputum sample is not proof of NTM disease, especially
when the acid-fast-bacillus smear is negative and NTM are
cultured in small numbers. The distinction between colo-
nization or contamination and true infection is often diffi-
cult and somewhat arbitrary. 
In 1997, the American Thoracic Society issued a revised
statement of diagnostic criteria for NTM lung disease (1)
(Table 5), and in 2000, the British Thoracic Society pub-
lished guidelines for the management of NTM disease (2).
According to the British guidelines, which had less strict di-
agnostic criteria than those of the American Thoracic
Society statement, NTM pulmonary disease is diagnosed
when positive cultures develop from specimens of sputum
obtained at least seven days apart (positive culture, twice)
from a patient whose chest radiograph suggests mycobacte-
rial infection and who may or may not present with symp-
toms or signs (2).
The American Thoracic Society diagnostic criteria put
relatively great emphasis on multiple culture and identifi-
cation using at least three sputum samples; the invasive
bronchoscopic approach includes bronchial washing and
transbronchial lung biopsy and HRCT, especially in pa-
tients without cavitary infiltrates. These criteria were con-
sidered by some investigators as being primarily designed
Koh et al.
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Table 4. Radiologic Findings of Nontuberculous Mycobacterial
Pulmonary Disease
Species Radiologic Findings
M. avium  Upper lobe cavitary form




bilateral nodular or interstitial/nodular infiltrates
predominantly in the right middle lobe and
lingular segment of the left upper lobe;
multiple small nodules combined with
bronchiectasis at HRCT
M. kansasii thin-walled cavities in the upper lobes;
pleural effusion, lower lobe
involvement-uncommon
Rapidly growing interstitial, interstitial/alveolar, and/or
mycobacteria reticulonodular;
M. abscessus cavitation-uncommon
M. fortuitum In M. chelonae pulmonary infection,
M. chelonae multiple small nodules, diffuse bronchiectasis,
focal areas of consolidation at CT
Note. HRCT=high-resolution computed tomography
Table 5. American Thoracic Society Criteria for the Diagnosis of Nontuberculous Mycobacterial Pulmonary Disease
Clinical criteria
1. Compatible symptoms and signs
2. Reasonable exclusion of other disease
Radiographic criteria
1. Plain chest radiography
Infiltrates with or without nodules (persistent  2 months, or progression)
Cavitation
Nodules alone (multiple)
2. High-resolution computed tomography (HRCT)
Multiple small nodules
Multifocal bronchiectasis with or without small lung nodules
If three sputum/bronchial wash results are available from the previous 12 months:
1. Three positive cultures with negative acid-fast bacilli smear results, or
2. Two positive cultures and one positive acid-fast bacilli smear
If only one bronchial wash is available:
1. Positive culture with a 2+, 3+, or 4+ acid-fast bacilli smear, or 2+, 3+, or 4+ growth on solid media
If sputum/bronchial wash evaluations are nondiagnostic or another disease cannot be excluded:
1. Transbronchial or lung biopsy yielding nontuberculous mycobacteria, or
2. Biopsy showing mycobacterial histopathologic features (granulomatous inflammation or acid-fast bacilli smear) and one
or more sputa or bronchial washing procedures positive for nontuberculous mycobacterium, even in low numbersfor use in the United States, where the incidence of tuber-
culosis is low and the relative incidence of NTM pul-
monary disease is high (29). In developing countries,
where the incidence of pulmonary tuberculosis is much
higher than that of NTM pulmonary disease, the initiation
of presumptive antituberculous treatment, especially in
smear-positive patients prior to the identification of iso-
lates, is common practice. With empirical first-line antitu-
berculous treatment, early sputum conversion to culture-
negativity would be expected in some cases of NTM pul-
monary disease, reducing the likely success of attempts to
obtain further positive culture of isolates. Thus, patients in
whom the isolate of NTM has been initially identified but
who show less than three isolations from their sputum ex-
aminations cannot meet the American Thoracic Society’s
diagnostic criteria. In developing countries, where my-
cobacterial culture and identification of multiple specimens
of sputum are not routine practice because of the high inci-
dence of tuberculosis and high cost of multiple mycobacte-
rial culture and identification, a solution to these problems
would be of particular value to clinicians (30). Whether the
American Thoracic Society’s diagnostic approach could be
feasible for other developing countries such as Korea is not
yet clear, and remains to be demonstrated by the findings
of further studies.
In general, evidence of disease, such as infiltration visible
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Fig. 1. A 46-year-old woman with M. avium infection.
A. Initial chest radiograph shows cavitary lesions (arrows) in both upper lobes. Also note that bilateral reticulonodular lesions are present
in upper and middle lung zones.
B. High-resolution (1.0-mm collimation) CT scan obtained at the level of the thoracic inlet, and at the same time as A, depicts a cavitary
lesion with pleural thickening in the right apex. Nodules (arrows) project from the wall of the cavitation into its lumen.
C. CT scan obtained at the level of the inferior pulmonary vein shows centrilobular nodules and branching linear structures (arrows) in
both lungs, suggesting the bronchogenic spread of disease. Also note the presence of bronchiectasis in the right middle lobe.
D. Follow-up radiograph obtained 31 months after A, and after treatment, shows some increase in the extent of reticulonodular lesions,
especially in left upper and middle lung zones (arrows).
CD
ABat chest radiography, the cause of which has not been de-
termined by careful clinical and laboratory studies, and the
repeated isolation of multiple colonies of the same strain of
NTM in the absence of other pathogens, are sufficient for
the diagnosis of NTM pulmonary disease (1).
Because NTM pulmonary disease can be quite indolent,
the importance of appropriate follow-up to determine the
significance of potentially pathogenic NTM isolated from
sputum cannot be overemphasized. Delays in diagnosis are
frequent, and radiographs may remain unchanged for
years: in one series, an average of 6.4 years passed before
radiographic change was apparent (31). Where NTM cul-
tures are positive, stable findings at chest radiography, es-
pecially at relatively short intervals, are not sufficient
grounds to exclude infection. In the absence of lung biop-
sy, months to years of clinical, radiographic, and microbio-
logical follow-up of certain patients may be required to re-
liably determine the significance of NTM respiratory iso-
lates (1).
LABORATORY METHODS 
The methods of acid-fast staining and culture currently
used to discover M. tuberculosis are acceptable for most
Koh et al.
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Fig. 2. A 67-year-old woman with M. avium infection.
A. Initial chest radiograph reveals airspace consolidation in the right upper lobe and reticulonodular lesions (arrows) in the right middle,
and left middle and lower, lung zones.
B. High-resolution (1.0-mm collimation) CT scan obtained at the level of the bronchus intermedius, and at the same time as A, shows air-
space consolidation (arrows) at the bottom of the right upper lobe, and bronchiectasis and small centrilobular nodules (small arrows) in
the lingular segment of the left upper lobe.
C. CT scan obtained at the level of the right basal trunk depicts centrilobular nodules and branching linear structures (arrows), an acinar
nodule (curved arrows), lobular consolidation (open arrows), and bronchiectasis.
D. Follow-up radiograph obtained 31 months after A, and after treatment, shows that in both lungs, disease is less extensive.
CD
ABNTM species. The appearance of NTM at microscopy is
generally indistinguishable from that of M. tuberculosis,
and the American Thoracic Society has recommended that
samples should be inoculated onto at least one solid medi-
um (Lowenstein-Jensen or Middlebrook 7 H10 and 7 H11)
and into a liquid culture system (BACTEC, MGIT, ESP);
the latter allows more rapid culture and isolation of a
greater range of species than does the use of solid media
alone (1), though at present, many microbiology laborato-
ries in Korea use only Lowenstein-Jensen solid media.
NTM are identified by their pattern of pigmentation,
growth characteristics, microscopic appearance, and bio-
chemical reactions. More rapid discriminating systems are
being developed, and include DNA probes, high-perfor-
mance liquid chromatography, polymerase chain reaction
restriction enzyme analysis, and 16S rRNA gene sequence
analysis (1, 2).
In NTM infections, susceptibility testing is more difficult
and more controversial than in those due to M. tuberculo-
sis. In general, the results of standard susceptibility tests
are of little or no value in predicting clinical efficacy in
NTM infections, and the provision of in-vitro susceptibility
results to clinicians is likely to be confusing rather than
helpful (1, 2). Both the American and the British Thoracic
Society have recommended that routine testing of the sus-
ceptibility of NTM to antituberculous drugs be discouraged
(1, 2).
Mycobacterium avium COMPLEX (MAC)
PULMONARY DISEASE
MAC is the most commonly isolated and most clinically
important pulmonary NTM pathogen, and includes the two
species M. avium and M. intracellulare. The fact that they
are distinct has no clinical or prognostic value for individ-
ual patients, however, and they are generally not differen-
tiated.
The symptoms and signs of MAC lung disease are vari-
able and nonspecific and, in addition, the natural history of
MAC lung disease in HIV-negative patients is unpre-
dictable. Some show a stable clinical and radiographic pic-
ture for years, while in others, progression of their disease
is relatively rapid. This feature appears to relate in part to
the existence of two types of clinical disease and presenta-
tion.
MAC pulmonary disease has been recently differentiated
into two distinct subtypes, the upper lobe cavitary form
(Fig. 1) and the nodular bronchiectatic form (Fig. 2) (1).
The former, the traditional and most widely known pre-
sentation of MAC pulmonary disease, is usually seen in
white, middle-aged or elderly men who smoke or abuse al-
cohol. Underlying disorders commonly include chronic ob-
structive pulmonary disease, previous tuberculosis, and sili-
cosis. Chest radiography frequently demonstrates apical
cavitary change similar to that seen in reactivated tubercu-
losis (20 23, 32). Cavitation is common and frequently as-
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Fig. 3. A 78-year-old man with M. kansasii infection.
A. Chest radiograph reveals the presence of reticulonodular lesions in both upper lobes, which have decreased in volume. Also note
right apical pleural thickening and emphysematous overinflation in remaining lung areas.
B. High-resolution (1.0-mm collimation) CT scan obtained at the level of the aortic arch shows consolidation containing the open
bronchus sign in the right upper lobe and thin-walled cavity (small arrows), and some areas of consolidation (arrows) in the left upper
lobe. Also note the reduced volume of both upper lobes.
ABsociated with apical pleural thickening; the cavities are usu-
ally small and thin-walled (20, 27, 28). Endobronchial
spread of disease is also common and manifests as unilater-
al or bilateral scattered nodular areas of increased opacity
(Fig. 1). Adenopathy and pleural effusion are uncommon,
though progressive fibrosis with volume loss and traction
bronchiectasis in the upper lobes occurs in one-third of pa-
tients (22, 23, 32). This form of disease is generally pro-
gressive, and if left untreated can lead to extensive lung
destruction and death (1).
A second and less dramatic clinical presentation, the so-
called nodular bronchiectatic form, has recently been rec-
ognized (1) (Fig. 2), and occurs predominantly in nonsmok-
ing middle-aged or elderly women who also present with
chronic cough and sputum production. Interestingly, previ-
ous or underlying lung disease has not been noted in these
patients (33, 34). In addition, the radiographic findings are
quite distinct from those of the classical upper lobe cavi-
tary form of the disease: the characteristic findings are bi-
lateral nodular or interstitial/nodular change, predominant-
ly in the lower lung zones, and particularly in the right
middle lobe and lingular segment of the left upper lobe
(33, 34). The apical pattern resembling reactivated tuber-
culosis is not present. 
This type of disease often used to be referred to as air-
way colonization, where the real underlying condition was
bronchiectasis. Several previous investigators have sup-
ported the concept of “colonization” (defined as isolation
of the organism from the respiratory tract, without evi-
dence of tissue invasion) (21), and recent studies involving
the use of HRCT scanning have indicated that these pa-
tients show specific radiographic features of parenchymal
disease in addition to multifocal areas of bronchiectasis.
Typical HRCT findings are multiple small nodules (< 5
mm) and branching linear structures combined with
bronchiectasis in the same lobe of the lung, features which
are usually confined to or most severe in the right middle
lobe and lingular segment of the left upper lobe (Fig. 2)
(25 28). In addition, transbronchial lung biopsy specimens
show granulomatous inflammation, suggesting lung tissue
invasion by the organisms involved (35). One recent study
demonstrated that the characteristic pathologic finding of
pulmonary MAC disease is extensive granuloma formation
throughout the airways (36). Both the HRCT and the
pathologic findings are considered to be due to the pres-
ence of mycobacterial disease, and the term ‘colonization’
may, therefore, be inappropriate (1).
In nodular bronchiectasis, isolation of MAC from sputum
specimens is less consistent than in the upper lobe cavitary
form of the disease: sputum may be intermittently positive
and/or positive, with low numbers of organisms. A recent-
ly published report showed that because of high false-nega-
tive rates of sputum cultures in such a population, 45% of
patients required bronchoscopy or lung biopsy to diagnose
active MAC infection (37). This low sensitivity of sputum
cultures may result from the non-cavitary nature of the dis-
ease.
In some patients, the condition initially involves the pres-
Koh et al.
152 Korean J Radiol 3(3), September 2002
Fig. 4. A 54-year-old woman with M. abscessus infection.
A. Chest radiograph depicts patchy areas of reticulonodular lesions in the entire right and left upper lung.
B. High-resolution (1.0-mm collimation) CT scan obtained at the level of the aortic arch demonstrates bronchiectasis, small nodules, and
ground-glass opacity in the right upper lobe.
C. Reformed coronal image depicts bronchiectasis, small nodules, and ground-glass opacity in the entire right lung.
AB Cence of small peripheral nodules, with the subsequent de-
velopment of infiltrate and bronchiectasis in adjacent
parenchyma (35). One study using serial CT examinations
demonstrated the progression of existing bronchiectasis as
well as the formation of new areas (38), results which
strongly suggest that in some patients at least, bronchiecta-
sis may not only be a predisposing condition for MAC in-
fection but also be caused by it.
The nodular bronchiectatic form of MAC disease tends
to progress much more slowly than the cavitary form, and
over time may gradually lead to respiratory failure. In the
original report of this disease (33), the condition was pro-
gressive in eight (38%) of the 21 immunocompetent adult
patients involved. Four (50%) of the eight died after pro-
gression during the longitudinal follow-up period led to
respiratory failure (33). Patients with this new clinical pre-
sentation of MAC pulmonary disease accounted for 25%
of the total number of HIV-negative cases in that first re-
port, and subsequent reviews have indicated that this pa-
tient population accounts for 50% of MAC pulmonary dis-
ease cases (39).
Historically, medical treatment of MAC pulmonary dis-
ease in HIV-negative patients has been disappointing.
Before the introduction the macrolides in the 1990s, multi-
drug regimens, usually including isoniazid, rifampin,
ethambutol and streptomycin, had been recommended
(40): this combination therapy provided initial sputum con-
version rates of approximately 50 to 70%, with the long-
term success rate of less than 50% mainly due to treatment
failure and relapses (1, 41). The newer macrolides, clar-
ithromycin and azithromycin, have had a great impact on
the treatment of this disease, with recent studies showing
excellent in-vitro and clinical results (42 44). For the
treatment of adults without HIV infection, the American
Thoracic Society recommended a regimen of clar-
ithromycin or azithromycin, rifampin or rifabutin, and
ethambutol, to be taken daily. Streptomycin should also be
considered, especially for patients who have radiographi-
cally extensive or cavitary disease, and particularly when
this is accompanied by strongly positive sputum smears (1). 
Reports of experiences with these regimens have men-
tioned sputum conversion rates of up to 90% in patients
with no history of previous treatment failure and tolerance
of all three oral drugs (42 44). All patients treated with
macrolides show clinical improvement within 3 to 6
months, and sputum conversion occurs within 12 months
(43). Treatment is continued until sputum cultures are con-
secutively negative for at least one year (1).
Mycobacterium kansasii PULMONARY DISEASE
Unlike other NTM, M. kansasii has never been found in
soil or natural water supplies, but has been discovered in
piped water systems in cities where it is endemic. Previous
studies have demonstrated that M. kansasii disease is con-
centrated in urban areas, supporting a possible association
between clinical disease and the presence of the organism
in potable water supplies (1).
The clinical and radiological features of pulmonary dis-
ease caused by M. kansasii usually resemble those of pul-
monary tuberculosis. Such disease presents more frequent-
ly in older men, and a history of cigarette abuse and chron-
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Fig. 5. A 33-year-old man with M. fortui-
tum infection.
A. Chest radiograph shows focal opacifi-
cation of the right upper lung zone. 
B. High-resolution (1.0-mm collimation)
CT scan obtained at the level of the aor-
tic arch shows nodules of various sizes in
the right upper lobe. The dominant nod-
ule contains internal cavitation (arrow).
ABic obstructive pulmonary disease is found in more than
50% of patients (45).
The radiographic features of M. kansasii pulmonary dis-
ease are very similar to those of pulmonary tuberculosis.
Cavitation occurs in about 90% of cases, with a prepon-
derance of upper lobe involvement (Fig. 3), and in some
cases, the cavities tend to have thinner walls and less sur-
rounding parenchymal infiltration than in tuberculosis (21,
46). The differences are not sufficient to permit differential
diagnosis on the basis of the radiographic findings alone,
though the presence of pleural effusion or lower lobe in-
volvement makes M. kansasii infection very unlikely (47).
The natural history of pulmonary disease caused by M.
kansasii in patients receiving no drug treatment has shown
persistent sputum production and progressive clinical and
radiologic disease (1). With rifampin-containing regimens,
however, sputum conversion rates are almost 100%, and
treatment failure and long-term relapse rates are very low
(48). The American Thoracic Society recommendation for
treatment of pulmonary disease caused by M. kansasii in-
cludes isoniazid, rifampin, and ethambutol. Medication is
usually administered daily for 18 months, and a minimum
of 12 months of negative sputum cultures indicates success-
ful treatment (1).
Koh et al.
154 Korean J Radiol 3(3), September 2002
Fig. 6. A 37-year-old woman with M. chelonae infection.
A. Initial chest radiograph depicts reticulonodular lesions in both lungs, especially in the upper and middle zones.
B. High-resolution (1.5-mm collimation) CT scan obtained at the level of the main bronchi, and at the same time as A, shows centrilobu-
lar nodules and branching linear structures (arrows) in both lungs.
C. CT scan obtained at the level of the right inferior pulmonary vein reveals bronchiectasis in both lungs, which contain centrilobular nod-
ules (arrows).




Most clinical pulmonary disease is due to three clinically
relevant species of rapidly growing mycobacteria (RGM):
M. abscessus, M. fortuitum, and M. chelonae. Among the
pulmonary diseases these cause, M. abscessus (formerly
Mycobacterium chelonae, subspecies abscessus) is respon-
sible for approximately 80% of isolates, and M. fortuitum
for a further 15% (49, 50). 
RGM pulmonary disease patients tend to be middle-aged
or older, female, and nonsmokers (49). Specific underlying
diseases, which are infrequent and occur in only approxi-
mately 20% of patients, include prior mycobacterial infec-
tion, gastroesophageal disorders with chronic vomiting,
and bronchiectasis (49, 50). As in other forms of NTM lung
disease, the symptoms are indolent and diagnosis is usually
not established until more than two years after the thier
onset (49). 
The most frequent patterns seen at chest radiography are
interstitial, interstitial/alveolar, and/or reticulonodular den-
sities (Figs. 4 6). Cavitation occurs in only 15% of pa-
tients (49). The disease is typically multilobar and bilateral,
with slight upper lobe predominance (49, 51). The most
common CT findings in patients with M. chelonae infection
are diffuse bronchiectasis, multiple small lung nodules, fo-
cal areas of consolidation, and bronchial wall thickening,
and are similar to those reported for MAC pulmonary dis-
ease (52) (Fig. 6).
In most patients with M. abscessus without underlying
disorder, the disease progresses very slowly, and some pa-
tients show little radiographic change over a period of
years. According to one report, in which the outcomes of
154 patients with RGM pulmonary disease were reviewed,
death was attributed directly to progressive RGM lung dis-
ease, accompanied by respiratory failure in 21 cases (14%)
(49).
The treatment of M. abscessus is complex. Isolates are
generally susceptible only to parenteral antibiotics such as
amikacin, cefoxitin and imipenem, and the newer oral
macrolides, though the organism is very difficult to eradi-
cate. A report of 154 patients infected with RGM (49) stat-
ed that only ten infected with M. abscessus were cured.
Seven of these ten received parenteral antibiotics for 1 to 3
months, followed by surgical excision, whereas only three
were successfully treated with antibiotics alone. Surgical
resection of localized disease is thought to be the most ef-
fective way of achieving complete eradication of the or-
ganism (1, 49).
M. fortuitum, which is usually more susceptible to multi-
ple oral antimicrobial agents, including the newer
macrolides and quinolones, doxycycline and minocycline,
and sulfonamides, requires a different approach, and for
this species, drug susceptibility testing is crucial. Clinical
cure usually results from 6 to 12 months of therapy with
two oral agents to which the M. fortuitum isolate is suscep-
tible in vitro (1).
CONCLUSION
The incidence of NTM pulmonary diseases is increasing,
while that of tuberculosis is decreasing. In Korea, the M.
avium complex and rapidly growing mycobacteria such as
M. abscessus, M. chelonae, and M. fortuitum are reported
to account for most of the pathogens responsible for NTM
pulmonary infection. Because of the low sensitivity of spu-
tum smears and culture, diagnosis of NTM pulmonary dis-
ease, especially in its non-cavitary forms, is often difficult.
In patients in whom chest radiographs depict bilateral
bronchiectasis and reticulonodular infiltrates that are con-
fined to or most severe in the right middle lobe and lingu-
lar segment of the left upper lobe, NTM pulmonary dis-
ease, especially nodular bronchiectatic forms of MAC dis-
eases, should be suspected, and an aggressive diagnostic
approach including HRCT and bronchoscopy should be
considered. For the correct diagnosis and treatment of
NTM pulmonary disease, physicians and radiologists must
fully understand the various clinical and radiographic find-
ings described. 
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